MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
MoonLake Immunotherapeutics
NASDAQ:MLTXHealthcare · Biotechnology
-6.28%$11.78
AH$11.70-0.68%vs close
Mkt Cap$1B
Float54.6M
O/S85.11M
Vol
$ Vol
RVOL
Inst Own86.0%
SI14.3%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$227.32M
Total Assets$424.43M
Free Cash Flow-$196.04M
Debt & Equity
Debt 20%
Equity 80%
Total Debt$75.71M
Total Equity$304.48M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in MLTX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$424.43M
Liabilities$119.95M
Accounts Receivable$4.87M
Accounts Payable$0
Inventory$0
PP&E (Net)$2.14M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $2.62M | $0 | $0 | $0 | $5K | $0 |
| Gross Profit | -$2.62M | $0 | $0 | $0 | -$5K | $0 |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $202.86M | $112.77M | $31.8M | $42.05M | $35.52M | $0 |
| Selling, General, and Administrative | $41.97M | $30.32M | $22.32M | $23.01M | $18.05M | $106K |
| Other | -$2.62M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $242.22M | $143.09M | $54.12M | $65.06M | $53.57M | $106K |
| Operating Income (EBIT) | -$244.83M | -$143.09M | -$54.12M | -$65.06M | -$53.58M | -$106K |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $7.25M | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $15K |
| Other Income (Expense) | $15.12M | $22.13M | $10.14M | $592K | -$62K | $15K |
| Income Before Tax (EBT) | -$229.71M | -$120.96M | -$43.98M | -$64.47M | -$53.64M | -$91K |
| Income Tax Expense | $611K | $282K | $94K | $36K | $5K | $0 |
| Net Income | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -$53.64M | -$91K |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -3.53 | -1.89 | -0.73 | -1.70 | -1.45 | -0.01 |
| Diluted EPS | -3.53 | -1.89 | -0.73 | -1.70 | -1.45 | -0.01 |
| Weighted Average OS | 64.46M | 62.87M | 49.12M | 29.36M | 36.93M | 14.80M |
| EBITDA | -$219.85M | -$119.58M | -$43.61M | -$64.3M | -$53.63M | -$91K |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $334.52M | $180.43M | $451.17M | $39.51M | $8.04M | $1.34M |
| Short-Term Investments | $59.45M | $267.6M | $59.84M | $32.61M | $0 | $0 |
| Cash and Short-Term Investments | $393.97M | $448.03M | $511.01M | $72.11M | $8.04M | $1.34M |
| Accounts Receivable | $4.87M | $2.84M | $1.06M | $217K | $149K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $421.69M | $474.29M | $514.17M | $76.51M | $9.64M | $1.62M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $2.14M | $3.64M | $3.95M | $332K | $46K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $115.04M | $115.01M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $596K | $0 | $8.42M | $0 | -$115.04M | $0 |
| Total Long-Term Assets | $2.74M | $3.64M | $12.37M | $332K | $46K | $115.01M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $424.43M | $477.93M | $526.54M | $76.84M | $9.68M | $116.63M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $0 | $8.68M | $1.46M | $47K | $1.23M | $0 |
| Short-Term Debt | $1.23M | $0 | $0 | $0 | $15M | $58K |
| Current Income Tax Payable | $0 | $642K | $368K | $110K | $64K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $40.83M | $4.24M | $2.78M | $110K | $1.3M | $67K |
| Total Current Liabilities | $45.48M | $22.46M | $9.97M | $7.67M | $21.09M | $125K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $74.47M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | -$374K | $621K | $583K | $282K | $240K | $4.03M |
| Total Long-Term Liabilities | $74.47M | $2.08M | $3.08M | $411K | $240K | $4.03M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $119.95M | $24.54M | $13.05M | $8.08M | $21.33M | $4.15M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $72K | $0 |
| Common Stock | $7K | $6K | $6K | $5K | $39K | $115M |
| Retained Earnings | -$462.91M | -$235.59M | -$116.66M | -$80.65M | -$53.64M | -$2.52M |
| Comprehensive Income & Other | $604K | $5M | $2.36M | $351K | -$168K | $0 |
| Other Stockholders' Equity | $767.38M | $682.41M | $612.33M | $129.54M | $41.96M | $0 |
| Total Equity | $304.48M | $446.82M | $495.68M | $48.9M | -$11.65M | $112.48M |
| Minority Interest | $0 | $6.57M | $17.82M | $19.87M | $0 | $0 |
| Total Liabilities and Equity | $424.43M | $471.37M | $508.72M | $56.97M | $9.68M | $116.63M |
| Supplementary Data | ||||||
| Total Debt | $75.71M | $2.83M | $3.7M | $283K | $15M | $58K |
| Net Debt | -$258.81M | -$177.6M | -$447.47M | -$39.22M | $6.96M | -$1.28M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$229.1M | -$121.24M | -$44.08M | -$64.51M | -$53.64M | -$91K |
| Depreciation & Amortization | $2.62M | $1.38M | $370K | $165K | $5K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $12.9M | $7.28M | $7.11M | $9.65M | $10.86M | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$2.02M | -$1.79M | -$840K | -$68K | -$149K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $1.57M | $0 |
| Other Working Capital | $21.9M | -$2M | -$5.38M | -$1.51M | $3.06M | -$216K |
| Total Working Capital Change | $19.88M | -$3.78M | -$6.22M | -$1.58M | $4.48M | -$216K |
| Other Non-Cash Items | -$2.3M | -$226K | $43K | $372K | $3.12M | -$10K |
| Net Cash from Operating | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -$35.18M | -$317K |
| Investing Activities | ||||||
| Capital Expenditures | -$35K | -$520K | -$284K | -$16K | -$51K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$265.37M | -$350.28M | -$175.73M | -$42.23M | $0 | -$115M |
| Sales of Investments | $468.4M | $145.2M | $150.83M | $9.9M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $202.99M | -$205.6M | -$25.18M | -$32.34M | -$51K | -$115M |
| Financing Activities | ||||||
| Debt Repaid | -$73.02M | - | - | $15M | - | - |
| Common Stock Issuance | $72.97M | $52.54M | $482.45M | $4K | $28.27M | $117M |
| Common Stock Repurchases | $0 | -$50 | $0 | $0 | -$6K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$1.23M | -$2.75M | $134.69M | $0 | -$347K |
| Net Cash from Financing | $146M | $51.31M | $479.7M | $119.69M | $43.26M | $116.65M |
| Forex Effect | $1.11M | $128K | -$76K | $9K | -$1.33M | $0 |
| Net Change in Cash | $154.09M | -$270.74M | $411.66M | $31.47M | $6.7M | $1.34M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -$35.18M | -$317K |
| Capital Expenditure | -$35K | -$520K | -$284K | -$16K | -$51K | $0 |
| Free Cash Flow | -$196.04M | -$117.11M | -$43.06M | -$55.91M | -$35.23M | -$317K |
| Cash at Beginning | $180.43M | $451.17M | $39.51M | $8.04M | $1.34M | $0 |
| Cash at End | $334.52M | $180.43M | $451.17M | $39.51M | $8.04M | $1.34M |